SAFETY AND EFFECTIVENES OF IMMUNE GLOBULIN INTRAVENOUS

静脉注射免疫球蛋白的安全性和有效性

• 批准号: 7952022
• 负责人: RAYMOND SCOTT TURNER
• 金额: $ 0.43万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952022
• 关键词: Albumins; Alzheimer' s Disease; Biological Markers; Categories; Cholinesterase Inhibitors; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; DNA Library; Dementia; Dose; Funding; Grant; Healthcare; Infusion procedures; Institution; Intravenous Immunoglobulins; Magnetic Resonance Imaging; Measures; Memantine; Placebos; Plasma; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; base; instrument; neuropsychiatry; routine therapy; trial comparing

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a (Category A) NIA-ACDS/Baxter Healthcare-sponsored 20 month (76 wk) trial comparing two doses of IVIG (200 or 400 mg/kg, q 2wk x 36 infusions) with placebo (0.25% albumin) to decrease the progression of dementia due to mild-moderate Alzheimer's disease already on routine therapy (cholinesterase inhibitors or memantine). Primary endpoints are based on ADAS-Cog and ADAS-CGIC instruments. Secondary measures are other neuropsychiatric measures, resource utilization, safety and tolerability, plasma biomarkers, and changes in (noncontrast) MRI. There are optional sub-studies which would allow 10y banking of DNA, repeated LP for CSF biomarkers (at baseline, 9 mo, and 18 mo), and/or FDG-PET (at baseline and 9 mo).

这个子项目是众多研究子项目之一